ONO Pharmaceutical Co., Ltd.

Nvidia CEO Jensen Huang unveiled a broad slate of AI products, partnerships, and customer deployments at the company's Japan AI event in Tokyo on July 15. The announcements spanned physical AI, healthcare, financial services, quantum computing, automotive, manufacturing, and gaming, highlighting Nvidia's push to position its technologies at the forefront of Japan's next-generation AI infrastructure. In physical AI and robotics, Nvidia launched Cosmos 3 Edge for on-device vision reasoning, and companies including FANUC, Fujitsu, Hitachi, Kawasaki Heavy Industries, Kubota, NEC, SoftBank, Sony Group, and Yaskawa Electric plan to join the Nvidia Cosmos Coalition to develop open physical AI models. In healthcare, Astellas Pharma, Eisai, Daiichi Sankyo, Ono Pharmaceutical, and Takeda Pharmaceutical are deploying Nvidia BioNeMo for AI-powered drug discovery, while Canon and Fujifilm introduced Nvidia-powered next-generation CT systems, and Kawasaki Heavy Industries is advancing AI-enabled surgical and hospital robots. In financial services, Mizuho Financial plans Japan's largest on-premises AI factory for banking, Sumitomo Mitsui Financial has deployed an AI factory through Japan Research Institute, and Rakuten Bank is developing AI transaction foundation models using Nvidia Agent Toolkit. Huang emphasized that the next wave of AI will be physical AI—robots, factories, vehicles, and industrial systems that can perceive, reason, and act in the real world—and said Japan's leadership in robotics, manufacturing, and precision engineering positions it to play a leading role in this transition.

Deciphera Pharmaceuticals announced the first patient has been dosed in the global pivotal Phase 3 INTREPID study evaluating sapablursen for the treatment of polycythemia vera, a rare and potentially life-threatening hematologic disease. The study will compare the efficacy and safety of sapablursen to placebo over a 32-week double-blind treatment period followed by up to 124 weeks of open-label treatment, with the primary endpoint being response defined by the absence of phlebotomy eligibility. Sapablursen has received Fast Track, Orphan Drug, and Breakthrough Therapy designations from the U.S. Food and Drug Administration. The trial has initiated in the United States and is planned in additional regions including North America, Latin America, Asia Pacific, and Europe. Deciphera is a member of Ono Pharmaceutical, which obtained exclusive global rights to sapablursen through a license agreement with Ionis Pharmaceuticals in March 2025.